Plain-English translation of NCT06175000 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a targeted antibody medication, can help keep brain lymphoma from coming back after you've already completed your initial chemotherapy. The study will compare two groups: one that receives the medication regularly for 2 years, and one that receives regular monitoring without additional treatment. Researchers want to see if this maintenance approach helps people stay in remission longer.
Brain lymphoma can return even when patients initially respond well to chemotherapy. Doctors are exploring whether continuing treatment with this medication after initial chemotherapy might prevent relapse and help people stay healthy longer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will receive intravenous infusions of the medication every 60 days for 2 years (with the first cycle involving two days of treatment). The other group will be monitored closely with regular check-ups and brain imaging for 2 years without additional medication. Throughout the study, you'll have visits to check your health, brain imaging scans, blood tests, and possibly some assessments of how the treatment affects your thinking and quality of life.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States